Top

Published in:

01-09-2008 | Research Paper

Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapedesis

Authors: Linda Sequeira, Cara W. Dubyk, Tracy A. Riesenberger, Carlton R. Cooper, Kenneth L. van Golen

Published in: Clinical & Experimental Metastasis | Issue 5/2008

Abstract

Background The Rho GTPases comprise one of the eight subfamilies of the Ras superfamily of monomeric GTP-binding proteins and are involved in cytoskeletal organization. Previously, using a dominant negative construct, we demonstrated a role for RhoC GTPase in conferring invasive capabilities to PC-3 human prostate cancer cells. Further, we demonstrated that inactivation of RhoC led to morphological changes commensurate with epithelial to mesenchymal transition (EMT) and was accompanied by increased random, linear motility and decreased directed migration and invasion. EMT was related positively to sustained expression and activity of Rac GTPase. In the current study we analyze the individual roles of RhoA, RhoC and Rac1 GTPases in PC-3 cell directed migration, invasion and tumor cell diapedesis across a human bone marrow endothelial cell layer in vitro. Results Use of specific shRNA directed against RhoA, RhoC or Rac1 GTPases demonstrated a role for each protein in maintaining cell morphology. Furthermore, we demonstrate that RhoC expression and activation is required for directed migration and invasion, while Rac1 expression and activation is required for tumor cell diapedesis. Inhibition of RhoA expression produced a slight increase in invasion and tumor cell diapedesis. Conclusions Individual Rho GTPases are required for critical aspects of migration, invasion and tumor cell diapedesis. These data suggest that coordinated activation of individual Rho proteins is required for cells to successfully complete the extravasation process; a key step in distant metastasis.

American Cancer Society (2008) Cancer facts & figures 2008

Alcover J, Fernandez-Conde M, Carrere W, Serrallach M, Carretero P (1994) Treatment of tumor osteopathy in cancer of the prostate. Actas Urol Esp 18(Suppl):409–416PubMed

Abate-Shen C, Shen MM (2000) Molecular genetics of prostate cancer. Genes Dev 14:2410–2434. doi:10.1101/gad.819500 PubMedCrossRef

Aukerman SL, Price JE, Fidler IJ (1986) Different deficiencies in the prevention of tumorigenic-low-metastatic murine K-1735b melanoma cells from producing metastases. J Natl Cancer Inst 77:915–924PubMed

Price JE, Aukerman SL, Fidler IJ (1986) Evidence that the process of murine melanoma metastasis is sequential and selective and contains stochastic elements. Cancer Res 46:5172–5178PubMed

Cooper CR, Pienta KJ (2000) Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a mini review. Prostate Cancer Prostatic Dis 3:6–12. doi:10.1038/sj.pcan.4500387 PubMedCrossRef

Cooper CR, McLean L, Walsh M et al (2000) Preferential adhesion of prostate cancer cells to bone is mediated by binding to bone marrow endothelial cells as compared to extracellular matrix components in vitro. Clin Cancer Res 6:4839–4847PubMed

Lehr JE, Pienta KJ (1998) Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 90:118–123. doi:10.1093/jnci/90.2.118 PubMedCrossRef

Ridley AJ (1994) Membrane ruffling and signal transduction. Bioessays 16:321–327. doi:10.1002/bies.950160506 PubMedCrossRef

10.

Evers EE, van der Kammen RA, ten Klooster JP, Collard JG (2000) Rho-like GTPases in tumor cell invasion. Meth Enzymol 325:403–415. doi:10.1016/S0076-6879(00)25461-X PubMedCrossRef

11.

Hall A (1998) Rho GTPases and the actin cytoskeleton. Science 279:509–514. doi:10.1126/science.279.5350.509 PubMedCrossRef

12.

Esteve P, Embade N, Perona R et al (1998) Rho-regulated signals induce apoptosis in vitro and in vivo by a p53- independent, but Bcl2 dependent pathway. Oncogene 17:1855–1869. doi:10.1038/sj.onc.1202082 PubMedCrossRef

13.

Gampel A, Parker PJ, Mellor H (1999) Regulation of epidermal growth factor receptor traffic by the small GTPase rhoB. Curr Biol 9:955–958. doi:10.1016/S0960-9822(99)80422-9 PubMedCrossRef

14.

Yao H, Dashner E, van Golen CM, van Golen KL (2006) RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility. Oncogene 25:2285–2296. doi:10.1038/sj.onc.1209260 PubMedCrossRef

15.

Hakem A, Sanchez-Sweatman O, You-Ten A et al (2005) RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 19:1974–1979. doi:10.1101/gad.1310805 PubMedCrossRef

16.

Simpson KJ, Dugan AS, Mercurio AM (2004) Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res 64:8694–8701. doi:10.1158/0008-5472.CAN-04-2247 PubMedCrossRef

17.

West K, Zhang H, Brown M et al (2004) The LD4 motif of paxillin regulates cell spreading and motility through an interaction with paxillin kinase linker (PKL). J Cell Biol 154:161–176. doi:10.1083/jcb.200101039 CrossRef

18.

van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD (2000) RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2:418–425. doi:10.1038/sj.neo.7900115 PubMedCrossRef

19.

Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD (2002) Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 160:579–584PubMed

20.

Hendrix MJ, Seftor EA, Seftor RE, Fidler IJ (1987) A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 38:137–147. doi:10.1016/0304-3835(87)90209-6 PubMedCrossRef

21.

van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD (2000) RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60:5832–5838PubMed

22.

Aktories K, Hall A (1989) Botulinum ADP-ribosyltransferase C3: a new tool to study low molecular weight GTP-binding proteins. Trends Pharmacol Sci 10:415–418. doi:10.1016/0165-6147(89)90191-0 PubMedCrossRef

23.

Aktories K, Braun U, Rosener S, Just I, Hall A (1989) The rho gene product expressed in E. coli is a substrate of botulinum ADP-ribosyltransferase C3. Biochem Biophys Res Commun 158:209–213. doi:10.1016/S0006-291X(89)80199-8 PubMedCrossRef

24.

Walsh PC (1994) Prostate cancer kills: strategy to reduce deaths. Urology 44:463–466. doi:10.1016/S0090-4295(94)80039-1 PubMedCrossRef

25.

Kjoller L, Hall A (1999) Signaling to Rho GTPases. Exp Cell Res 253:166–179. doi:10.1006/excr.1999.4674 PubMedCrossRef

26.

Takai Y, Sasaki T, Matozaki T (2001) Small GTP-binding proteins. Physiol Rev 81:153–208PubMed

27.

Price LS, Collard JG (2001) Regulation of the cytoskeleton by Rho-family GTPases: implications for tumour cell invasion. Semin Cancer Biol 1:167–173. doi:10.1006/scbi.2000.0367 CrossRef

28.

Sahai E, Marshall CJ (2002) RHO-GTPases and Cancer. Nat Rev Cancer 2:133–142. doi:10.1038/nrc725 PubMedCrossRef

29.

van Golen KL, Davies S, Wu ZF et al (1999) A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 5:2511–2519PubMed

30.

Suwa H, Ohshio G, Imamura T et al (1998) Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 77:147–152PubMed

31.

Imamura F, Mukai M, Ayaki M et al (1999) Involvement of small GTPases Rho and Rac in the invasion of rat ascites hepatoma cells. Clin Exp Metastasis 17:141–148. doi:10.1023/A:1006598531238 PubMedCrossRef

32.

Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532–535. doi:10.1038/35020106 PubMedCrossRef

33.

Fritz G, Just I, Kaina B (1999) Rho GTPases are over-expressed in human tumors. Int J Cancer 81:682–687. doi:10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B PubMedCrossRef

34.

Moscow JA, He R, Gnarra JR et al (1994) Examination of human tumors for rhoA mutations. Oncogene 9:189–194PubMed

35.

del Peso L, Hernandez-Alcoceba R, Embade N et al (1997) Rho proteins induce metastatic properties in vivo. Oncogene 15:3047–3057. doi:10.1038/sj.onc.1201499 PubMedCrossRef

36.

Marionnet C, Lalou C, Mollier K et al (2003) Differential molecular profiling between skin carcinomas reveals four newly reported genes potentially implicated in squamous cell carcinoma development. Oncogene 22:3500–3505. doi:10.1038/sj.onc.1206571 PubMedCrossRef

37.

Horiuchi A, Imai T, Wang C et al (2003) Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 83:861–870PubMed

38.

Kamai T, Tsujii T, Arai K et al (2003) Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9:2632–2641PubMed

39.

Shinto E, Tsuda H, Matsubara O, Mochizuki H (2003) Significance of RhoC expression in terms of invasion and metastasis of colorectal cancer. Nippon Rinsho 61(Suppl 7):215–219PubMed

40.

Wang W, Yang LY, Yang ZL, Huang GW, Lu WQ (2003) Expression and significance of RhoC gene in hepatocellular carcinoma. World J Gastroenterol 9:1950–1953PubMed

41.

Kondo T, Sentani K, Oue N, Yoshida K, Nakayama H, Yasui W (2004) Expression of RHOC is associated with metastasis of gastric carcinomas. Pathobiology 71:19–25. doi:10.1159/000072958 PubMedCrossRef

42.

Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG (1999) Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J Cell Biol 147:1009–1022. doi:10.1083/jcb.147.5.1009 PubMedCrossRef

43.

Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A (1992) The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70:401–410. doi:10.1016/0092-8674(92)90164-8 PubMedCrossRef

44.

Ridley AJ, Hall A (1992) The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70:389–399. doi:10.1016/0092-8674(92)90163-7 PubMedCrossRef

45.

Arthur WT, Burridge K (2001) RhoA inactivation by p190RhoGAP regulates cell spreading and migration by promoting membrane protrusion and polarity. Mol Biol Cell 12:2711–2720PubMed

46.

Burbelo PD, Miyamoto S, Utani A et al (1995) p190-B, a new member of the Rho GAP family, and Rho are induced to cluster after integrin cross-linking. J Biol Chem 270:30919–30926. doi:10.1074/jbc.270.52.30919 PubMedCrossRef

47.

Tikoo A, Czekay S, Viars C et al (2000) p190-A, a human tumor suppressor gene, maps to the chromosomal region 19q13.3 that is reportedly deleted in some gliomas. Gene 257:23–31. doi:10.1016/S0378-1119(00)00387-5 PubMedCrossRef

48.

Wennerberg K, Forget M-A, Ellerbroek SM et al (2003) Rnd Proteins function as RhoA antagonists by activationg p190 RhoGAP. Curr Biol 13:1106–1115. doi:10.1016/S0960-9822(03)00418-4 PubMedCrossRef

49.

Riento K, Vilalonga P, Garg R, Ridley AJ (2005) Function and Regulation of RhoE. Biochem Soc Trans 33:649–651. doi:10.1042/BST0330649 PubMedCrossRef

50.

Wang H-R, Zhan Y, Ozdamar B et al (2003) Regulation of cell polarity and protrusion formation by targeting RhoA for degredation. Science 302:1775–1779. doi:10.1126/science.1090772 PubMedCrossRef

51.

Sahai E, Marshall CJ (2003) Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 5:711–719. doi:10.1038/ncb1019 PubMedCrossRef

52.

Wittchen ES, van Buul JD, Burridge K, Worthylake RA (2005) Trading spaces: Rap, Rac, and Rho as architects of transendothelial migration. Curr Opin Hematol 12:14–21. doi:10.1097/01.moh.0000147892.83713.a7 PubMedCrossRef

Title: Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapedesis
Authors: Linda Sequeira
Cara W. Dubyk
Tracy A. Riesenberger
Carlton R. Cooper
Kenneth L. van Golen
Publication date: 01-09-2008
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 5/2008
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-008-9173-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2008

Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis

Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity

Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition

SOD derivatives prevent metastatic tumor growth aggravated by tumor removal

Single-cell tumor dormancy model of uveal melanoma

A highly bone marrow metastatic murine breast cancer model established through in vivo selection exhibits enhanced anchorage-independent growth and cell migration mediated by ICAM-1

Keynote webinar | Spotlight on antibody–drug conjugates in cancer